Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study

Agnese Paderi [1,†], Sara Fancelli [1,†], Enrico Caliman [1,2], Serena Pillozzi [1], Elisabetta Gambale [1], Marinella Micol Mela [1], Laura Doni [1], Francesca Mazzoni [1] and Lorenzo Antonuzzo [1,2,*]

Supplementary material

Table S1. Incidence of irAEs in NSCLC population.

	NSCLC n=67 (%)	<70 n=27 (%)	≥70 n=40 (%)	p (<70 vs ≥70)
Type of irAEs	irAes n = 39	irAEs n = 10	irAEs n = 19	
Pneumonitis	6 (9.0)	4 (14.8)	2 (5.0)	*p=0.168*
Colitis	6 (9.0)	2 (7.4)	4 (10.0)	*p=0.715*
Hepatitis	1 (1.5)	1 (3.7)	0 (0.0)	*p=0.220*
Skin reactions	11 (16.4)	1 (3.7)	10 (25.0)	***p=0.021***
Rheumatological	5 (7.5)	2 (7.4)	3 (7.5)	*p=0.989*
Endocrine related	12 (17.9)	8 (29.6)	4 (10.0)	***p=0.040***

Table S2. Incidence of irAEs in melanoma population.

	melanoma n=46 (%)	<70 n=17 (%)	≥70 n=29 (%)	p (<70 vs ≥70)
Type of irAEs	irAes n = 32	irAes n = 18	irAes n = 14	
Pneumonitis	4 (8.7)	2 (11.8)	2 (6.9)	*p=0.572*
Colitis	8 (17.4)	4 (23.5)	4 (13.8)	*p=0.400*
Hepatitis	1 (2.2)	1 (5.9)	0 (0.0)	*p=0.187*
Skin reactions	7 (15.2)	2 (11.8)	5 (17.2)	*p=0.618*
Rheumatological	4 (8.7)	3 (17.6)	1 (3.4)	*p=0.099*
Endocrine related	8 (17.4)	6 (35.3)	2 (6.9)	***p=0.014***

Table S3. Incidence of irAEs in RCC population.

	RCC n= 33 (%)	<70 n=13 (%)	≥70 n=20 (%)	p (<70 vs ≥70)
Type of irAEs	irAes n = 40	irAes n = 17	irAes n = 23	
Pneumonitis	4 (12.1)	0 (0.0)	4 (20.0)	*p=0.085*
Colitis	5 (15.5)	2 (15.4)	3 (15.0)	*p=0.976*
Hepatitis	4 (12.1)	2 (15.4)	2 (10.0)	*p=0.643*
Skin reactions	9 (27.3)	3 (23.1)	6 (30.0)	*p=0.663*
Rheumatological	4 (12.1)	3 (23.1)	1 (5.0)	*p=0.120*
Endocrine related	14 (42.4)	7 (53.8)	7 (35.0)	*p=0.284*